Drug intelligence / Profile preview

GSK2434735

Development stage: Phase 1
Lead developer: GSK
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

GSK2434735 is a bispecific antibody developed by GSK (formerly GlaxoSmithKline) that targets both interleukin-13 (IL-13) and interleukin-4 (IL-4). Its mechanism of action involves inhibiting the activity of these cytokines, which are implicated in the pathogenesis of asthma and other immune-mediated respiratory diseases. The drug was investigated primarily as an antiasthmatic agent. Clinical development included a phase 1 trial assessing pharmacokinetics, immunogenicity, safety, and tolerability in healthy volunteers. Development for asthma has been discontinued[1][2][3][4].

Targets

IL-13 (Interleukin-13)IL-4 (Interleukin 4)

Beyond the preview

Go deeper on GSK2434735.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2434735.

Explore the full profile